VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
CBT101
Phase 1
Small molecule
C
Ceres Brain Therapeutics
1
Indications
1
Total Trials
1
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Intranasal Administration
Recruiting
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Intranasal Administration
Phase 1
Recruiting
Clinical
Trials by Indication
[1]
Intranasal Administration
1 trial
Intranasal Administration of Dodecyl Creatine Ester (CBT101) in Healthy Male Subjects
Recruiting
·
C
Ceres Brain Therapeutics
·
Phase 1
·
NCT07050316
·
48 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for CBT101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
CBT101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for CBT101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Ceres Brain Therapeutics company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 1
[1]
Company
C
Ceres Brain Therapeutics
Related News